Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody

BACKGROUND: Ideally, monoclonal antibodies provide selective treatment by targeting the tumour, without affecting normal tissues. Therefore, antibody imaging is of interest, preferably in early stages of drug development. However, the imaging signal consists of specific, as well as non-specific, upt...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:EJNMMI Res
Auteurs principaux: Jauw, Yvonne W. S., Huisman, Marc C., Nayak, Tapan K., Vugts, Danielle J., Christen, Randolph, Naegelen, Valerie Meresse, Ruettinger, Dominik, Heil, Florian, Lammertsma, Adriaan A., Verheul, Henk M. W., Hoekstra, Otto S., van Dongen, Guus A. M. S., Menke-van der Houven van Oordt, C. Willemien
Format: Artigo
Langue:Inglês
Publié: Springer Berlin Heidelberg 2018
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5778091/
https://ncbi.nlm.nih.gov/pubmed/29356983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-018-0358-8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires